Kratom is not legally classified as a narcotic in the United States, but its main active compounds bind to the same brain receptors that narcotics do. This puts kratom in an unusual gray zone: it acts on opioid pathways, can cause dependence and withdrawal, yet remains unscheduled at the federal level. The answer depends on whether you’re asking about the legal label or the pharmacology.
What “Narcotic” Actually Means
The word “narcotic” carries two different meanings depending on who’s using it. In medicine, narcotics are opioids, drugs that relieve pain by binding to mu-opioid receptors in the brain and spinal cord. Morphine, oxycodone, and fentanyl all fall into this category. In law enforcement and legal contexts, “narcotic” is broader and sometimes vaguer, referring to any substance controlled under drug scheduling laws.
Kratom doesn’t fit neatly into either definition. It is not scheduled under the federal Controlled Substances Act, so legally it is not a narcotic. But pharmacologically, its active chemicals behave like opioids in important ways. The FDA has noted that kratom’s two primary alkaloids, mitragynine and 7-hydroxymitragynine, bind to the same mu-opioid receptors as drugs like codeine. The agency also states these compounds “may produce classic opioid-related effects such as sedation, nausea/vomiting, constipation, physical dependence/withdrawal, and respiratory depression.”
How Kratom Works on Opioid Receptors
Kratom leaves contain over 50 alkaloids, but two do most of the heavy lifting. Mitragynine is the most abundant, making up the bulk of the alkaloid content. It binds to mu-opioid receptors with moderate affinity. The second compound, 7-hydroxymitragynine, is present in much smaller amounts but binds to those same receptors roughly nine times more strongly.
What makes these compounds unusual is how they activate the receptor. Traditional opioids like morphine trigger two major signaling pathways: one that produces pain relief (G-protein signaling) and another linked to side effects like slowed breathing (beta-arrestin recruitment). Research published in the Journal of the American Chemical Society found that mitragynine and 7-hydroxymitragynine activate the pain-relief pathway but produce no measurable beta-arrestin recruitment. Scientists describe this as “biased” signaling, and it may partly explain why kratom’s main alkaloid appears to carry a lower risk of respiratory depression compared to conventional opioids.
Kratom also acts on other brain systems beyond opioid receptors. Mitragynine interacts with serotonin, dopamine, and norepinephrine pathways. This is one reason kratom’s effects feel different from a standard opioid: at low doses, many users report stimulant-like effects such as increased energy and alertness, while higher doses tend to produce sedation and pain relief more typical of opioids.
Respiratory Depression: A Key Safety Difference
The most dangerous feature of traditional narcotics is their ability to slow breathing to the point of death. Kratom’s two main alkaloids behave very differently from each other on this front. In animal studies, mitragynine did not cause respiratory depression at any dose tested. It actually increased breathing rate, an effect that was not reversed by naloxone (the standard opioid overdose antidote), suggesting it works through a non-opioid mechanism.
7-hydroxymitragynine, on the other hand, caused dose-dependent respiratory depression similar to morphine, and naloxone fully reversed it. This is a significant safety concern, especially because newer concentrated kratom products and synthetic extracts can contain far higher levels of 7-hydroxymitragynine than raw kratom leaves. Some semi-synthetic products on the market contain up to 98% 7-hydroxymitragynine, effectively turning a botanical product into something that behaves much more like a classical opioid.
Dependence and Withdrawal
One of the hallmarks of narcotics is their ability to create physical dependence, and kratom shares this trait. Regular users can develop tolerance, needing more to achieve the same effect, and experience withdrawal symptoms when they stop. Kratom withdrawal looks a lot like mild to moderate opioid withdrawal: sweating, irritability, anxiety, muscle aches, nausea, and insomnia. The Mayo Clinic notes that people who use kratom over time may develop cravings and sometimes need the same medications used to treat opioid use disorder.
This is one of the strongest arguments for viewing kratom as functionally similar to a narcotic, even if the label doesn’t officially apply. If you’ve been using kratom regularly for weeks or months, stopping abruptly can produce real physical symptoms. They tend to be less severe than withdrawal from potent prescription opioids, but they are unmistakably opioid-like in character.
Current Legal Status
Kratom and its alkaloids are not regulated at the federal level in the United States. The DEA considered emergency scheduling kratom in 2016 but withdrew the proposal after public backlash. As of mid-2025, the FDA recommended that the DEA classify synthetic 7-hydroxymitragynine under the Controlled Substances Act, but that step targets the concentrated synthetic version rather than the raw plant or standard kratom products.
A handful of states and local jurisdictions have banned kratom independently, but most of the country allows its sale. Internationally, kratom is not under control through any United Nations treaty. The World Health Organization reviewed kratom and its alkaloids through its Expert Committee on Drug Dependence but has not recommended international scheduling.
This patchwork means kratom occupies a legal space very different from scheduled narcotics. You can buy it in most states without a prescription, often at gas stations, smoke shops, and online retailers. That accessibility doesn’t reflect a consensus that it’s safe. It reflects the fact that regulation hasn’t caught up with the science.
Why the Classification Matters
Whether you call kratom a narcotic shapes how people think about it. Labeling it as one could discourage use among people who benefit from it as a harm-reduction tool for opioid withdrawal, something some users report finding helpful even though clinical evidence remains limited. On the other hand, treating it as a harmless herbal supplement ignores the genuine opioid activity, dependence potential, and respiratory risks associated with concentrated products.
The most accurate framing is that kratom contains compounds that act as atypical opioids. Its primary alkaloid, mitragynine, behaves differently enough from classical narcotics to potentially carry a better safety profile for breathing suppression. But 7-hydroxymitragynine, especially in concentrated or synthetic form, behaves much more like a traditional opioid. And regardless of which alkaloid dominates a given product, regular use can lead to dependence and withdrawal that mirrors what happens with scheduled narcotics.
If you’re using kratom or considering it, the practical takeaway is straightforward: it is not a narcotic by legal definition, but it activates opioid pathways in your brain, and your body can become dependent on it. Treating it with the same respect you’d give any opioid-acting substance is reasonable, particularly with the higher-potency extracts now widely available.